Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...
Multiple Sclerosis News Today

Briumvi outperforms Aubagio in highly active relapsing MS: Study

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...
Healio

Stem cell transplant suppresses relapse in multiple sclerosis up to 4 years

Please provide your email address to receive an email when new articles are posted on . Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At ...